Does Retatrutide Cause Hair Loss? What the Evidence Shows

Does Retatrutide Cause Hair Loss? What the Phase 2 Trial Actually Reported

Several pages currently ranking for this question answer it flatly: retatrutide does not cause hair loss, based on clinical trial data. That answer is built on a real observation and then stretched past what the observation supports.

The real observation: retatrutide's Phase 2 trial, published by Jastreboff and colleagues in the New England Journal of Medicine in 2023, includes a full adverse-event and safety table. That table covers any adverse event, serious adverse events, deaths, events leading to discontinuation, every event occurring in at least 5% of participants, and a separate category of adverse events of special interest. Alopecia and hair loss appear in none of those lists, at any dose tested.

That is a precise, sourced statement about one trial's published table. It is not a statement about the drug. Turning "not reported in this trial" into "does not cause hair loss" requires the trial to have been capable of detecting the effect, and a single 48-week study in 338 participants was not designed for that job.

What the Trial Did Capture

The safety table is not sparse. The most frequently reported events were gastrointestinal: nausea, diarrhea, constipation, and vomiting, mostly mild to moderate and dose-dependent, which matches the pattern across the GLP-1 class. Discontinuations were attributed to nausea, vomiting, diarrhea, dyspepsia, and increased lipase.

One detail cuts against the "nobody was looking" reading. The trial reported cutaneous hyperesthesia and skin sensitivity in 7% of participants receiving retatrutide versus 1% on placebo, and listed it as an event of special interest. So a skin-adjacent category was tracked closely enough to be quantified against placebo. Hair loss still didn't surface. That makes the absence more informative than blanket silence would be. It still isn't proof of anything about follicles.

Why Retatrutide Has No Hair-Loss Data Yet

Here is the part most pages skip. The hair-loss signal for semaglutide and tirzepatide did not come from their pivotal trials either. It came later, from a completely different kind of study.

Herrera and Bordeaux published a retrospective TriNetX cohort analysis in the Journal of the American Academy of Dermatology in 2026, drawing on the health records of large numbers of people already taking semaglutide or tirzepatide. Gupta and colleagues published a systematic review in Science Progress the same year, pulling in pharmacovigilance database signals. Both methods require a drug that has been prescribed to a very large population over a long period. Neither can be run on a drug that is still in trials.

Retatrutide is in exactly that position. It is investigational, with Phase 3 ongoing and no marketed population to mine. Its peer-reviewed trial record runs to roughly a thousand participants across Phase 2 and early Phase 3, against the millions of prescriptions behind the semaglutide and tirzepatide signals. The four TRIUMPH trials, which are the largest datasets the program has produced, have not been published at all yet. Headline results have gone out by press release, and a press release reports a primary endpoint and a handful of common side effects, not a full adverse-event table. It cannot tell you anything about a dermatologic signal in either direction. When a 2025 scoping review surveyed alopecia across GLP-1 receptor agonists, retatrutide was not discussed anywhere in it, because there was nothing to discuss.

So the honest framing is not "retatrutide looks clean on hair loss." It is that retatrutide has not yet been through the type of study that would find out. Semaglutide and tirzepatide both looked clean at the same stage of their evidence lifecycle. For more on where retatrutide sits in that lifecycle, see the retatrutide clinical trials overview and the TRIUMPH Phase 3 program, which is where the next tranche of safety data will come from.

The Mechanism: Why Rapid Weight Loss Triggers Hair Shedding

Every follicle on your scalp runs its own clock. Anagen is active growth and lasts two to seven years. Catagen is a roughly two-week transition where the follicle detaches from its blood supply. Telogen is a resting phase of about three months, after which the old hair falls out as new growth pushes it free. Normal shedding: 50 to 100 hairs a day.

A significant physiological stressor pushes a large group of follicles out of anagen at the same time. Roughly three months later, they shed together. That synchronized shedding is telogen effluvium, and the triggers are well established: surgery, serious illness, childbirth, and rapid weight loss. The 2024 JAAD case report by Gordon, Musleh, and Bordone described the effect in GLP-1 users as temporary and secondary to weight loss rather than a direct action on the follicle. Gupta and colleagues reached the same mechanistic conclusion in their 2026 systematic review of the GLP-1 class, in which semaglutide and tirzepatide showed the highest reported incidence.

The structural point: this mechanism isn't drug-specific. It's a response to the weight loss, whichever drug produced it. That's why it transfers to retatrutide as a reasonable expectation even though retatrutide has never been studied for it.

Retatrutide's Weight-Loss Magnitude, and Why It Only Supports an Inference

In its Phase 2 trial, retatrutide produced 24.2% mean body weight loss at 48 weeks on the 12mg dose. For context, tirzepatide produced 20.9% at 72 weeks on 15mg in SURMOUNT-1, and semaglutide produced 14.9% at 68 weeks on 2.4mg in STEP 1. These are three separate trials with different populations, different durations, and different designs. No head-to-head trial has compared them, so the numbers should be read as three independent results rather than a ranking.

With that caveat in place, the reasoning goes: if telogen effluvium tracks the magnitude and speed of weight loss, and retatrutide drives substantial weight loss, then hair shedding is a plausible experience for some retatrutide users. That is an inference from a shared class mechanism. It is not a finding about retatrutide, and it does not establish that retatrutide carries a higher hair-loss risk than any other drug. Nobody has measured that.

Community reports track with the inference. Discussions collected in our retatrutide Reddit roundup describe hair thinning appearing around the three to four month mark, which is the classic telogen effluvium timing. Those are self-reported anecdotes from an unverified population, not clinical evidence, and they should be weighted accordingly.

If You Notice Hair Shedding on Retatrutide, What Should You Do?

What follows is telogen effluvium management in general. None of it is retatrutide-specific, because no retatrutide-specific prevention data exists. Run any change past the clinician overseeing your treatment first.

• Protect protein intake. Hair shafts are almost entirely keratin. When appetite suppression cuts total intake sharply, protein is often the first thing to fall, and follicles are among the first structures the body deprioritizes. This is the single highest-value lever.
• Ask for a ferritin test, not just haemoglobin. Low stored iron is an independent risk factor for telogen effluvium even without weight loss. It is testable and correctable.
• Check zinc and vitamin D. Both are linked to follicle cycling and both are commonly low in people with obesity. A standard micronutrient panel covers them.
• Avoid extreme caloric restriction. Strong appetite suppression can leave people eating far below a safe floor without noticing. That amplifies follicle stress beyond what the weight loss alone would cause.
• Be skeptical of biotin. The evidence supports it mainly in people with a confirmed biotin deficiency. Without one, it is unlikely to change anything.
• See a dermatologist if the pattern is wrong. Telogen effluvium is diffuse and self-limiting. Patchy loss, shedding that persists past twelve months, or shedding alongside fatigue, cold intolerance, or brittle nails points somewhere else, such as androgenetic alopecia or thyroid dysfunction.

Should You Stop Retatrutide If You Notice Hair Shedding?

This is a conversation with whoever is prescribing or overseeing your retatrutide use, not a decision to make at home. Because retatrutide is investigational, that conversation belongs inside your clinical trial protocol or prescribing relationship, which is a stronger reason to route it through a clinician rather than a weaker one.

Two things to bring into it. Stopping doesn't switch shedding off: once a group of follicles has entered telogen, it runs through its roughly three-month resting phase whether or not the original stressor continues. And across the class more broadly, hair shedding alone is rarely treated as sufficient reason to abandon a therapy producing substantial metabolic benefit. How that applies to you is a clinical judgment, not a rule.

Retatrutide, Tirzepatide, and Semaglutide: What We Actually Know About Hair Loss

The clearest way to see the gap is to line up the evidence status rather than the outcomes. Three drugs, three very different depths of record.

Read the retatrutide column as blank space, not as a clean bill of health. Both approved drugs name hair loss on their own labels, at single-digit percentages against a 1% placebo rate. Retatrutide's column is empty because it has no label to name anything on, and no onset or recovery window because nobody has measured one. The two approved drugs have those windows only because they reached the market first and someone then counted. For a fuller treatment of each, see does tirzepatide cause hair loss and does semaglutide cause hair loss.